DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced positive interim results from Part 1a of its Phase 2 study of DM199 for the treatment of preeclampsia. The study, which is open-label and investigator-sponsored, demonstrated statistically significant reductions in both systolic and diastolic blood pressure, as well as a significant reduction in the uterine artery pulsatility index. Importantly, DM199 did not cross the placental barrier and was generally safe and well-tolerated. The study achieved pre-specified safety and efficacy endpoints, reinforcing DM199's therapeutic potential as a first-in-class, disease modifying therapy for preeclampsia. Currently, there are no approved pharmacological treatments for preeclampsia in the United States and Europe. DiaMedica Therapeutics plans to discuss these interim results further during a conference call and webcast scheduled for July 17, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。